704562--7/14/2006--PEREGRINE_PHARMACEUTICALS

related topics

{product, candidate, development}

{stock, price, share}

{property, intellectual, protect}

{product, liability, claim}

{provision, law, control}

{personnel, key, retain}

{regulation, change, law}

{control, financial, internal}

{product, market, service}

{competitive, industry, competition}

If We Cannot Obtain Additional Funding, Our Product Development And Commercialization Efforts May Be Reduced Or Discontinued And We May Not Be Able To Continue Operations. Successful Development Of Our Products Is Uncertain. To Date, No Revenues Have Been Generated From The Commercial Sale Of Our Products And Our Products May Not Generate Revenues In The Future. We Have Had Significant Losses And We Anticipate Future Losses. Our Product Development Efforts May Not Be Successful. Clinical Trials Required For Our Product Candidates Are Expensive And Time Consuming, And Their Outcome Is Uncertain. Success In Early Clinical Trials May Not Be Indicative Of Results Obtained In Later Trials. If We Successfully Develop Products But Those Products Do Not Achieve And Maintain Market Acceptance, Our Business Will Not Be Profitable. If We Cannot License Or Sell Cotara , It May Be Delayed Or Never Be Further Developed. Our Dependency On One Radiolabeling Supplier May Negatively Impact Our Ability To Complete Clinical Trials And Market Our Products. Our Manufacturing Facilities May Not Continue To Meet Regulatory Requirements And Have Limited Capacity. We May Have Significant Product Liability Exposure Because We Maintain Only Limited Product Liability Insurance. The Liquidity Of Our Common Stock Will Be Adversely Affected If Our Common Stock Is Delisted From The Nasdaq Capital Market. The Sale Of Substantial Shares Of Our Common Stock May Depress Our Stock Price. of Common Stock Reserved For Issuance of Common Stock Reserved For Issuance Our Highly Volatile Stock Price And Trading Volume May Adversely Affect The Liquidity Of Our Common Stock. If We Are Unable To Obtain, Protect And Enforce Our Patent Rights, We May Be Unable To Effectively Protect Or Exploit Our Proprietary Technology, Inventions And Improvements. We May Become Involved In Lawsuits To Protect Or Enforce Our Patents That Would Be Expensive And Time Consuming. We May Not Be Able To Compete With Our Competitors In The Biotechnology Industry Because Many Of Them Have Greater Resources Than We Do And They Are Further Along In Their Development Efforts. New And Potential New Accounting Pronouncements May Impact Our Future Financial Position And Results Of Operations If We Lose Qualified Management And Scientific Personnel Or Are Unable To Attract And Retain Such Personnel, We May Be Unable To Successfully Develop Our Products Or We May Be Significantly Delayed In Developing Our Products. Our Governance Documents And State Law Provide Certain Anti-Takeover Measures Which Will Discourage A Third Party From Seeking To Acquire Us Unless Approved By the Board of Directors.

Full 10-K form ▸

704562--7/14/2006--PEREGRINE_PHARMACEUTICALS_INC